Cesar Ulises Monjaras Avila

Dr. Cesar Ulises Monjaras Avila

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CACesar Ulises Monjaras Avila
Cesar Ulises Monjaras Avila
ALAna Cecilia Lorenzo-Leal
Ana Cecilia Lorenzo-Leal
ALAna Cecilia Luque-Badillo
Ana Cecilia Luque-Badillo
NDNinadh D’costa
Ninadh D’costa
CCClaudia Chavez-Munoz
Claudia Chavez-Munoz
Horacio BachHoracio Bach
Horacio Bach
Clear cell renal cell carcinoma (ccRCC) is a type of kidney cancer that arises from the cells lining the tubes of the kidney. The tumor immune microenvironment (TIME) of ccRCC is a complex interplay of various immune cells, cytokines, and signaling pathways. One of the critical features of the ccRCC TIME is the presence of infiltrating immune cells, including T cells, B cells, natural killer cells, dendritic cells, and myeloid-derived suppressor cells. Among these cells, CD8+ T cells are particularly important in controlling tumor growth by recognizing and killing cancer cells. However, the TIME of ccRCC is also characterized by an immunosuppressive environment that hinders the function of immune cells. Several mechanisms contribute to the immunosuppressive nature of the ccRCC TIME. For instance, ccRCC cells produce cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which suppress immune cell activation and promote the differentiation of regulatory T cells (Tregs). Tregs, in turn, dampen the activity of effector T cells and promote tumor growth. In addition, ccRCC cells can express programmed death-ligand 1 (PD-L1), which interacts with the programmed cell death protein 1 (PD-1) receptor on T cells to inhibit their function. In addition, other immune checkpoint proteins, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and lymphocyte activation gene 3 (LAG-3), also contribute to the immunosuppressive milieu of the ccRCC TIME. Finally, the hypoxic and nutrient-poor microenvironment of ccRCC can stimulate the production of immunosuppressive metabolites, such as adenosine and kynurenine, which further impair the function of immune cells. Understanding the complex interplay between tumor cells and the immune system in the ccRCC TIME is crucial for developing effective immunotherapies to treat this disease.

10 February 2020 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
NDNinadh M. D’cOsta
Ninadh M. D’cOsta
MLMatthew R. Lowerison
Matthew R. Lowerison
PRPeter A. Raven
Peter A. Raven
ZTZheng Tan
Zheng Tan
MRMorgan E. Roberts
Morgan E. Roberts
ASAlan I. So
Alan I. So
Background: Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine-kinase inhibitors (TKIs), sunitinib, as the first-line of treatment. Unfortunately, TKI resistance eventually develops, and the underlying molecular mechanism is not well understood. Methods: RCC cell-line with metastatic clear-cell histology (Caki-1), and patient samples were analysed to identify the role of Y-box binding protein 1 (YB-1) and ATP-binding cassette sub-family B member 1 (ABCB-1) in acquired sunitinib-resistance development. Caki-1 was conditioned with increasing sunitinib doses to recapitulate acquired resistance development in clinics. Sunitinib-conditioned and wild-type Caki-1 were subjected to cell viability assay, scratch assay, chicken embryo chorioallantoic membrane engraftment and proteomics analysis. Classical biochemical assays like flow cytometry, immunofluorescent staining, immunohistochemical staining, optical coherence tomography imaging, Western Blot and RT-PCR assays were applied to determine the possible mechanism of sunitinib-resistance development and the effect of drug treatments. Publicly available data was also used to determine the role of YB-1 upregulation in ccRCC and the patients’ overall survival. Results: We demonstrate that YB-1 and ABCB-1 are upregulated in sunitinib-resistant in vitro, ex vivo, in vivo and patient samples compared to the sensitive samples. This provides evidence to a mechanism of acquired sunitinib-resistance development in mccRCC. Furthermore, our results establish that inhibiting ABCB-1 with elacridar, in addition to sunitinib, has a positive impact on reverting sunitinib-resistance development in in vitro, ex vivo and in vivo models. Conclusion: This work proposes a targeted therapy (elacridar and sunitinib) to re-sensitize sunitinib-resistant mccRCC and, possibly, slow disease progression.

6 February 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NDNinadh M. D’cOsta
Ninadh M. D’cOsta
DCDavide Cina
Davide Cina
RSRaunak Shrestha
Raunak Shrestha
RBRobert H. Bell
Robert H. Bell
YLYen-Yi Lin
Yen-Yi Lin
ASAlan I. So
Alan I. So
Clear-cell renal cell carcinoma (ccRCC) is a common therapy resistant disease with aberrant angiogenic and immunosuppressive features. Patients with metastatic disease are treated with targeted therapies based on clinical features: low-risk patients are usually treated with anti-angiogenic drugs and intermediate/high-risk patients with immune therapy. However, there are no biomarkers available to guide treatment choice for these patients. A recently published phase II clinical trial observed a correlation between ccRCC patients’ clustering and their response to targeted therapy. However, the clustering of these groups was not distinct. Here, we analyzed the gene expression profile of 469 ccRCC patients, using featured selection technique, and have developed a refined 66-gene signature for improved sub-classification of patients. Moreover, we have identified a novel comprehensive expression profile to distinguish between migratory stromal and immune cells. Furthermore, the proposed 66-gene signature was validated using a different cohort of 64 ccRCC patients. These findings are foundational for the development of reliable biomarkers that may guide treatment decision-making and improve therapy response in ccRCC patients.

29 August 2022 in Odovtos - International Journal of Dental Sciences
Verified
Journal Article
Open access
PDF file
MMMargarita Mahetzi Martínez-Hernández
Margarita Mahetzi Martínez-Hernández
RGRamón González-Alamilla
Ramón González-Alamilla
JGJairo Eduardo Gutiérrez-Sánchez
Jairo Eduardo Gutiérrez-Sánchez
Carlos Cuevas-SuárezCarlos Cuevas-Suárez
Carlos Cuevas-Suárez
CACesar Ulises Monjaras Avila
Cesar Ulises Monjaras Avila
AÁAna Josefina Monjarás Ávila
Ana Josefina Monjarás Ávila
Bruxism is the repetitive muscle-mandibular behavior characterized by clenching and/or grinding of the teeth, which reflects the presence of one or more underlying conditions or factors. The objective of this descriptive study was to determine the association between bruxism and stress self-perceived during the pandemic, as well as their frequency by gender and academic area. An interrogation and self-perceived stress scale PSS-14 were applied to students from the different areas of the Institute of Health Sciences (ICSa) to determine the presence or absence of stress and bruxism symptom, a Chi-square was used for the comparison between variables, considering a value of p0.005. ICSa students between 18 and 24 age perceive symptoms of bruxism and high levels of stress caused during the pandemic.

7 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
CACesar Ulises Monjaras Avila
Cesar Ulises Monjaras Avila
DBDukagjin Blakaj
Dukagjin Blakaj
KHKenneth S. Hu
Kenneth S. Hu
KYKosj Yamoah
Kosj Yamoah
EGEmilio Gamez
Emilio Gamez
MGMauricio E. Gamez
Mauricio E. Gamez
Background/Objectives: Digital health encompasses telemedicine, mobile health (mHealth), wearable technologies, big data analytics, artificial intelligence (AI), machine learning (ML), and immersive technologies. In oncology, where care is complex, multidisciplinary, and longitudinal, these tools offer opportunities to enhance prevention, early detection, treatment planning, patient–clinician communication, survivorship, and palliative care. However, inconsistent definitions and ongoing ethical, regulatory, and implementation challenges hinder optimal integration. This review aims to synthesize current evidence on digital health in oncology and examine its applications across the cancer care continuum. Methods: A comprehensive narrative review of peer-reviewed literature was conducted, including clinical studies, trials, and systematic reviews evaluating digital health technologies in oncology. Evidence was organized according to key phases of the cancer care continuum, from prevention and diagnosis to treatment delivery, survivorship, and end-of-life care. Results: Digital health applications extend beyond virtual consultations. AI- and ML-driven systems support diagnostics, medical imaging, genomics, and treatment planning, while mHealth applications and wearable devices enable real-time symptom monitoring, toxicity reporting, and long-term follow-up. Digital education and communication platforms improve shared decision-making and patient engagement. Across diverse oncology settings, these tools demonstrate feasibility, high patient and clinician satisfaction, and potential improvements in care coordination and efficiency. Nevertheless, challenges related to data quality, interoperability, privacy, algorithmic bias, equity of access, and regulatory oversight persist. Conclusions: Digital health is increasingly embedded across the oncology care continuum and holds substantial promise for advancing personalized, patient-centred cancer care. Continued multidisciplinary collaboration, robust clinical validation, and responsible governance are essential to ensure safe, equitable, and clinically meaningful global implementation.

25 June 2025
Verified
Journal Article
Open access
CACesar Ulises Monjaras Avila
Cesar Ulises Monjaras Avila
ALAna Cecilia Luque-Badillo
Ana Cecilia Luque-Badillo
NCNicholas J Carr
Nicholas J Carr
APAnthony A Papp
Anthony A Papp
ASAlan I So
Alan I So
CCClaudia Chavez-Munoz
Claudia Chavez-Munoz
This study explores the potential for adipocyte-derived stem cells (ASCs) to be used in bladder reconstruction. Current methods, such as enterocystoplasty, have significant limitations, making new approaches necessary. Tissue engineering, specifically using acellular scaffolds such as the bladder acellular matrix, offers a promising basis for this development. For this study, ASCs were isolated from adipose tissue derived from liposuction and co-cultured with urothelial cells (UC; SV-HUC) to induce transdifferentiation. Results indicate successful isolation and characterization of ASCs, displaying positive markers for stem cells. The co-culture of ASCs with SV-HUC cells resulted in changes resembling epithelial cells, indicating a potential transdifferentiation process, and is corroborated by the mRNA and protein levels. For the functional assay, urothelial-like cells were seeded onto decellularized bladder tissues. These findings demonstrate the successful transdifferentiation of ASCs into functional UC, presenting a promising strategy for bladder reconstruction and a potential alternative to current approaches.